Filing Flows › Integra Lifesciences Holdings (IART) › Q4 2025
Integra Lifesciences Holdings (IART) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Integra Lifesciences Holdings (IART) reported revenue of $435M for the fourth quarter 2025 (Q4 2025), -2% from a year earlier and +8% from the quarter before. Operating margin was 5.3%, net loss $1.7M (0.4% of revenue).
Integra Lifesciences Holdings, Q4 2025: revenue $435M (-2% year over year), operating margin 5.3%, net loss $1.7M, operating cash flow $11.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $435M | +8% | -2% |
| Operating profit | $23.0M | +96% | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | $11.8M | -71% | -77% |
What changed
Revenue was $434.9M in Q4 2025, down 2% year over year and up 8% from the previous quarter. Codman Specialty Surgical was the largest line at 74% of revenue.
Operating profit was $23.0M, a 5.3% margin (down 2.8 points year over year). Total costs grew 1% against a revenue fall of 2%. The fastest-growing cost line was Cost of revenue (+11%). The quarter ended with a net loss of $1.7M, narrower than the previous quarter's $5.4M loss. Net interest and other expense of $18.7M was the main reason.
Operating cash flow was $11.8M (down 77% year over year). Non-cash charges added back $5.8M of share-based compensation. Working capital and other items added $7.7M. Capital expenditures of $17.2M exceeded it, leaving free cash flow of −$5.4M.
Questions
What was Integra Lifesciences Holdings' revenue in the fourth quarter 2025?
Integra Lifesciences Holdings (IART) reported revenue of $435M for the fourth quarter 2025 (Q4 2025), -2% from a year earlier and +8% from the quarter before.
Was Integra Lifesciences Holdings profitable in the fourth quarter 2025?
Operating profit was $23.0M (5.3% of revenue) and net loss $1.7M.